exv10w3



 





Exhibit 10.3
 



OPTION AGREEMENT




     This Option Agreement (“Option Agreement”) is made as of the 30th day of March, 2007 (the
“Effective Date”), by and between ReGen Biologics, Inc., a Delaware corporation (hereinafter
referred to as the “Company”), and the undersigned investor (together with its successors and
permitted assigns, the “Holder”).



RECITALS




     WHEREAS, in order to induce the Holder to enter into that certain Subscription Agreement
between the Company and the Holder dated as of March 30, 2007 (the “Subscription Agreement”), the
parties have entered into this Option Agreement granting to the Holder an option to purchase,
pursuant to the terms and conditions set forth herein, the Option Shares (as hereinafter defined);



     NOW, THEREFORE, BE IT RESOLVED, in consideration of the mutual covenants expressed herein and
for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, and intending to be legally bound, the parties agree as follows:



AGREEMENT





	 	1.	 	GRANT AND VESTING OF OPTION.






	 	(a)	 	Grant. Subject to the terms hereof, the Company hereby
grants to the Holder the option (the “Option”) to purchase from the Company
such number of shares (the “Option Shares”) of : (i) the Company’s Series D
Convertible Preferred Stock, $0.01 par value per share (the “Preferred Stock”),
equal to the number of shares purchased by the Holder pursuant to the Subscription Agreement; or (ii) if the Preferred Stock has been converted to shares of the Company’s Common Stock, $0.01 par value per share (the “Common
Stock”) pursuant to paragraph 7(a) of the Company’s Certificate of
Designations, Preferences and Rights of Series D Convertible Preferred Stock
(the “Mandatory Conversion”), such number of shares of Common Stock equal to
the number of shares of Common Stock such Holder would have been entitled to
receive upon conversion of the Preferred Stock such Holder purchased pursuant
to the Subscription Agreement.
	 
	 	(b)	 	Vesting. The Holder may exercise this Option upon, and
not later than fifteen (15) calendar days following, the Company’s public
announcement of receipt of Food and Drug Administration clearance of the
Company’s collagen scaffold device as a class II device (the last date of such
15-day period, the “Expiration Date”). In no event shall this Option be
exercised later than the Termination Date provided for below.




 









 












	 	(c)	 	Exercise Price. The “Exercise Price” (which shall be
subject to adjustment whenever there shall occur a stock split, combination,
reclassification or other similar event involving the Preferred Stock or the
Common Stock, as applicable) shall be (i) $42.00 per share of Preferred Stock
or (ii) if applicable pursuant to Paragraph 1(a)(ii) of this Option Agreement,
$0.42 per share of Common Stock.
	 
	 	(d)	 	Term. The Option shall terminate upon the earlier of
(i) the Expiration Date, (ii) December 31, 2007 (the “Termination Date”) and
(iii) partial exercise as provided by Section 2 below.






	 	2.	 	EXERCISE OF OPTION. In order to exercise the Option, the Holder must
present at the Company’s principal executive offices the following:






	 	(a)	 	the original Option Agreement together with a fully executed
Option Exercise Form in the form attached hereto and made a part hereof as
Exhibit A, including the representation to the Company that all of the
representations and warranties made by the Holder in Section 6(b) of this
Option Agreement are true and correct on the date of exercise; and
	 
	 	(b)	 	a certified or bank cashier’s check payable to the Company or a
wire transfer of immediately available funds in the amount of the product of
the Option Shares to be exercised and the Exercise Price (such amount, the
“Exercise Amount”).
	 
	 	The Company shall promptly thereafter deliver, or cause to be delivered, to the
Holder certificates for the number of Option Shares being purchased. If the Holder
elects to exercise the Option for less than all of the Options Shares subject
hereto, the option to purchase the remainder of the Option Shares shall immediately
terminate.






	 	3.	 	TRANSFER. This Option may not be transferred or assigned in any
manner, without the consent of the Company in its sole and absolute discretion.
	 
	 	4.	 	RIGHTS AND OBLIGATIONS OF THE HOLDER. The Holder shall not, by virtue
hereof, be entitled to any rights as a stockholder in the Company, either at law or in
equity; provided, however, in the event that any certificate representing Option Shares
is issued to the Holder upon exercise of some or all of the Option, the Holder shall,
for all purposes, be deemed to have become the holder of record of such Option Shares
on the date on which full payment of the Exercise Amount was made, irrespective of the
date of delivery of the certificate representing such Option Shares. The rights of the
Holder are limited to those expressed herein.
	 
	 	5.	 	REGISTRATION RIGHTS. The Holder shall have the following registration
rights with respect to the Option Shares:






	 	(a)	 	Required Registration. Following the Mandatory
Conversion, the Company agrees to register the resale of the Option Shares by
filing a




-2-









 












Registration Statement on Form S-1 or on any other form for which the
Company then qualifies and is available (the “Registration Statement”) with
the SEC within the earlier of (i) thirty (30) calendar days after the filing
of the Company’s Form 10-K for the prior fiscal year or (ii) ninety (90)
calendar days after the Expiration Date, or registering such Option Shares
on any Registration Statement filed by the Company. The Company shall
subsequently use commercially reasonable efforts to cause the SEC to declare
the Registration Statement effective as soon as possible. The Company shall
thereafter maintain the effectiveness of the Registration Statement until
the earlier of (a) the date on which all the Option Shares have been sold
pursuant to the Registration Statement or Rule 144 promulgated under the
Securities Act (“Rule 144”), (b) such time as the Company reasonably
determines, based on an opinion of counsel, that all of the holders of
options granted contemporaneously with the Option will be eligible to sell
under Rule 144 all of the Option Shares then owned by such holders within
the volume limitations imposed by paragraph (e) of Rule 144 in the three (3)
month period immediately following the termination of the effectiveness of
the Registration Statement, and (c) the first anniversary of the date the
Registration Statement was declared effective by the SEC. The Registration
Statement filed pursuant to this Section 5(a) may include other securities
of the Company that are held by individuals, partnerships, corporations,
business trusts, joint stock companies, estates, trusts, unincorporated
associations, joint ventures or other entities who, by virtue of agreements
with the Company, are entitled to similar registration rights.




	 	(b)	 	Registration Procedures.






	 	i.	 	In case of the Registration Statement effected
by the Company subject to this Section 5, the Company shall keep the
Holder advised in writing as to the initiation of such registration,
and as to the completion thereof. In addition, subject to Section 5(a)
above, the Company shall, to the extent applicable to the Registration
Statement:






	 	a)	 	prepare and file with the SEC
such amendments and supplements to the Registration Statement as
may be necessary to keep such registration continuously
effective and free from any material misstatement or omission
necessary to make the statements therein, in light of the
circumstances, not misleading, and comply with provisions of the
Securities Act with respect to the disposition of all securities
covered thereby during the period referred to in Section 5(a);
	 
	 	b)	 	update, correct, amend and supplement the Registration Statement as necessary;




-3-









 












	 	c)	 	notify the Holder promptly when
the Registration Statement is declared effective by the SEC, and
furnish such number of prospectuses, including preliminary
prospectuses, and other documents incident thereto as Holder may
reasonably request from time to time;
	 
	 	d)	 	use its commercially reasonable
efforts to register or qualify such Option Shares under such
other securities or blue sky laws of such jurisdictions of the
United States where an exemption is not available and as Holder
may reasonably request to enable it to consummate the
disposition in such jurisdiction of the Option Shares (provided
that the Company will not be required to (A) qualify generally
to do business in any jurisdiction where it would not otherwise
be required to qualify but for this provision, or (B) consent to
general service of process in any such jurisdiction, or (C)
subject itself to taxation in any jurisdiction where it is not
already subject to taxation);
	 
	 	e)	 	notify Holder at any time when a
prospectus relating to the Option Shares is required to be
delivered under the Securities Act, of the happening of any
event as a result of which the prospectus included in the
Registration Statement contains an untrue statement of a
material fact or omits any fact necessary to make the statements
therein not misleading and, subject to Section 5(a), the Company
will prepare a supplement or amendment to such prospectus, so
that, as thereafter delivered to purchasers of such shares, such
prospectus will not contain any untrue statements of a material
fact or omit to state any fact necessary to make the statements
therein, in light of the circumstances under which they were
made, not misleading;
	 
	 	f)	 	cause all such Option Shares to be listed on each securities exchange on which similar
securities issued by the Company are then listed and obtain all
necessary approvals for trading thereon;
	 
	 	g)	 	provide a transfer agent and registrar for all such Option Shares not later than the
effective date of the Registration Statement;
	 
	 	h)	 	upon the sale of any Option Shares pursuant to the Registration Statement, direct the
transfer agent to remove all restrictive legends from all
certificates or other instruments evidencing the Option Shares;
	 
	 	i)	 	With a view to making available
to the Holder the benefits of certain rules and regulations of
the SEC that at any time




-4-









 












permit the sale of the Option Shares to the public without
registration, so long as any Option Shares are outstanding,
the Company shall use its commercially reasonable efforts for
a period of two years following the Effective Date:




	 	(1)	 	to make and keep
public information available, as those terms are
understood and defined in Rule 144(c) under the
Securities Act;
	 
	 	(2)	 	to file with the
SEC in a timely manner all reports and other documents
required of the Company under the Exchange Act; and
	 
	 	(3)	 	to furnish to the
Holder upon any reasonable request a written statement
by the Company as to its compliance with the public
information requirements of Rule 144(c) under the
Securities Act; and






	 	j)	 	To advise the Holder promptly
after it has received notice or obtained knowledge of the
existence of any stop order by the SEC delaying or suspending
the effectiveness of the Registration Statement or of the
initiation or threat of any proceeding for that purpose, and to
make every commercially reasonable effort to obtain the
withdrawal of any order suspending the effectiveness of the
Registration Statement at the earliest possible time.






	 	ii.	 	Notwithstanding anything stated or implied to
the contrary in Section 5(b)(i) above, the Company shall not be
required to consent to any underwritten offering of the Option Shares
or to any specific underwriter participating in any underwritten public
offering of the Option Shares.
	 
	 	iii.	 	Each Holder agrees that upon receipt of any
notice from the Company of the happening of any event of the kind
described in Section 5(b)(i)(e), and subject to Section 5(d), such
Holder will forthwith discontinue such Holder’s disposition of Option
Shares pursuant to the registration statement relating to such Option
Shares until such Holder’s receipt of the copies of the supplemented or
amended prospectus contemplated by Section 5(b)(i)(e) and, if so
directed by the Company, will deliver to the Company at the Company’s
expense all copies, other than permanent file copies, then in such
Holder’s possession, of the prospectus relating to such Option Shares
current at the time of receipt of such notice.
	 
	 	iv.	 	Except as required by law, all expenses
incurred by the Company in complying with this Section 5, including but
not limited to, all registration, qualification and filing fees,
printing expenses, fees





-5-









 











and disbursements of counsel and accountants for the Company, blue
sky fees and expenses (including fees and disbursements of counsel
related to all blue sky matters) incurred in connection with any
registration, qualification or compliance pursuant to this Section 5
shall be borne by the Company. All underwriting discounts and
selling commissions applicable to a sale incurred in connection with
any registration of Option Shares and the legal fees and other
expenses of a Holder shall be borne by such Holder.




	 	(c)	 	Further Information. If Option Shares owned by a
Holder are included in any registration, such Holder shall furnish the Company
such information regarding itself as the Company may reasonably request and as
shall be required in connection with any registration (or amendment or
supplement thereto), referred to in this Agreement, and Holder shall indemnify
the Company with respect thereto in accordance with Section 9 hereof. The
Holder hereby represents and warrants to the Company that it has accurately and
completely provided the requested information and answered questions (a)
through (i) on the signature pages of the Subscription Agreement, and the
Holder agrees and acknowledges that the Company may rely on such information as
being true and correct for purposes of preparing and filing the Registration
Statement at the time of filing thereof and at the time it is declared
effective, unless the Holder has notified the Company in writing to the
contrary prior to such time.
	 
	 	(d)	 	Right of Suspension.






	 	i.	 	Notwithstanding any other provision of this
Agreement or any related agreement to the contrary, the Company shall
have the right, at any time, to suspend the effectiveness of the
Registration Statement and offers and sales of the Option Shares
pursuant thereto whenever, in the good faith judgment of the Company,
(i) continuing such effectiveness or permitting such offers and sales
could reasonably be expected to have an adverse effect upon the
Company’s ability to raise additional funds pursuant to one or more
private placements of shares of the Company or any debt securities of
the Company, a proposed sale of all or substantially all of the assets
of the Company or a merger, acquisition, reorganization,
recapitalization or similar current transaction materially affecting
the capital, structure, or equity ownership of the Company, (ii) the
Registration Statement must be suspended in order to register
additional shares of Preferred Stock or Common Stock, (iii) there
exists a material development or a potential material development with
respect to or involving the Company that the Company would be obligated
to disclose in the prospectus used in connection with the Registration
Statement, which disclosure, in the good faith judgment of the Company,
after considering the advice of counsel, would be premature or
otherwise inadvisable at such time, or (iv) the Registration





-6-









 











Statement or related prospectus or any document incorporated or
deemed to be incorporated therein by reference contains an untrue
statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements
therein, in light of the circumstances, not misleading, including
without limitation that period annually during which any Registration
Statement would require suspension pending the Issuer’s new fiscal
year financial statements (a “Suspension Event”). In the event that
the Company shall determine to so suspend the effectiveness of the
Registration Statement and offers and sales of the Option Shares
pursuant thereto, the Company shall, in addition to performing those
acts required to be performed under the Securities Act and/or the
Exchange Act or deemed advisable by the Company, deliver to each
Holder written notice thereof, signed by the Chief Financial Officer
or Chief Executive Officer of the Company. Upon receipt of such
notice, the Holders shall discontinue disposition of the Option
Shares pursuant to the Registration Statement and prospectus until
such Holders (x) are advised in writing by the Company that the use
of the Registration Statement and prospectus (and offers and sales
thereunder) may be resumed, (y) have received copies of a
supplemental or amended prospectus, if applicable, and (z) have
received copies of any additional or supplemental filings which are
incorporated or deemed to be incorporated by reference into such
prospectus. The Company will exercise commercially reasonable
efforts to ensure that the use of the Registration Statement and
prospectus may be resumed as quickly as practicable.




	 	ii.	 	The Company’s right to suspend the
effectiveness of the Registration Statement and the offers and sales of
the Option Shares pursuant thereto, as described above in this Section
5(d), shall be for a period of time (the “Suspension Period”) beginning
on the date of the occurrence of the Suspension Event and expiring on
the earlier to occur of (i) the date on which the Suspension Event
ceases, or (ii) ninety (90) days after the occurrence of the Suspension
Event; provided, however, that there shall not be more than two
Suspension Periods in any 12-month period. Notwithstanding the
foregoing, the Company shall be able to suspend the effectiveness of
the Registration Statement and offers and sales of the Option Shares
for any time period as may reasonably be required in order to update
the Registration Statement to replace financial information which is no
longer current, as required by applicable securities law.
	 
	 	iii.	 	In addition, in connection with any
underwritten public offering of securities of the Company, if requested
by the Company or its managing underwriter, each Holder will enter into
a lock-up





-7-









 











agreement pursuant to which such Holder will not, during the seven
(7) days prior to, and for a period no longer than one hundred eighty
(180) days following, the date of the prospectus (or if the offering
is pursuant to a shelf registration statement, the date of the
pricing prospectus supplement) relating to the offering, offer, sell
or otherwise dispose of any securities of the Company without the
prior consent of the Company and the managing underwriter, provided
that the executive officers and directors of the Company enter into
lock-up agreements for a period at least as long and on the same
terms.




	 	6.	 	COVENANTS.






	 	(a)	 	The Company covenants and agrees that all Option Shares
delivered upon exercise (in accordance with the terms and conditions set forth
herein) of the Option will, upon delivery, be duly and validly authorized and
issued, fully paid and non-assessable, and free from all liens and charges with
respect to the purchase thereof.
	 
	 	(b)	 	The Company covenants and agrees that this Option Agreement has
been duly and validly authorized, executed and delivered. In addition, the
Company agrees at all times to reserve and keep available an authorized number
of (i) shares of the Preferred Stock sufficient to permit the exercise in full
of the Option or (ii) after the Mandatory Conversion, shares of its Common
Stock sufficient to permit the exercise in full of the Option.






	 	7.	 	REPRESENTATIONS AND WARRANTIES.






	 	(a)	 	The Option Shares will not be registered under the Securities
Act of 1933, as amended, or the rules and regulations promulgated thereunder
(such Act and rules and regulations being hereinafter referred to as the “Act”)
or any state securities laws. The Holder agrees that the sale or any other
disposition of the Option Shares will be made in compliance with federal and
applicable state securities laws.
	 
	 	(b)	 	The Holder hereby represents and warrants to the Company as
follows:






	 	i.	 	it is an “accredited investor” within the
meaning of Rule 501 under the Act;
	 
	 	ii.	 	it is sophisticated and experienced in matters
of equity investing in general and in financial and business matters
related to the business of the Company in particular, capable of
evaluating the merits and risks of an investment in the Option and the
Option Shares;




-8-









 












	 	iii.	 	it is acquiring the Option and will acquire the
Option Shares for investment for its own account and not with a view to
any distribution thereof in violation of Federal or applicable state
securities laws;
	 
	 	iv.	 	this Option Agreement and the transactions
hereby have been duly approved by all requisite action of the Holder,
and the Holder has full power and authority to enter into and perform
its obligations under this Option Agreement, and to otherwise carry out
the transactions contemplated by this Option Agreement, without the
consent or approval of, notice to or registration with any person,
association, entity or governmental authority;
	 
	 	v.	 	this Option Agreement is a legal, valid and
binding obligation of the Holder enforceable in accordance with its
terms; and
	 
	 	vi.	 	the execution, delivery, performance and
consummation of this Option Agreement and the transactions provided for
herein do not and will not violate: (a) any contract, agreement or
other commitment to which the Holder is a party, or by which the Holder
is bound; or (b) any order, writ, injunction, decree, statute,
ordinance, rule or regulation applicable to the Holder.






	 	8.	 	FRACTIONAL SHARES. The Company shall not be required to issue any
fraction of a share of Preferred Stock or, after the Mandatory Conversion, any fraction
of a share of Common Stock, upon the exercise of the Option. If any fractional
interest in a share of Preferred Stock or Common Stock, as the case may be, shall be
deliverable upon the exercise of the Option (in whole or in part), the Company shall
make an adjustment therefor in cash equal to such fraction multiplied by the closing
price of the Preferred Stock or Common Stock, as the case may be, on the business day
directly preceding the day of exercise. If there is no closing price, then the
fraction shall be multiplied by the fair market value of a share of Preferred Stock or
Common Stock, as the case may be, as determined by the Board of Directors of the
Company.
	 
	 	9.	 	INDEMNIFICATION.






	 	(a)	 	Indemnification by the Company. The Company will
indemnify and hold harmless each Holder of Option Shares which are included in
a registration statement pursuant to the provisions of Section 5 hereof and any
underwriter (as defined in the Securities Act) for such Holder, and any person
who controls such Holder within the meaning of either Section 15 of the
Securities Act or Section 20 of the Exchange Act or such underwriter within the
meaning of the Securities Act, and any officer, director, investment adviser,
employee, agent, partner, member or affiliate of such Holder (each, a “Holder
Indemnified Party”), from and against, and will reimburse each such Holder
Indemnified Party with respect to,





-9-









 











any and all claims, actions, demands, losses, damages, liabilities, costs
and reasonably incurred expenses to which such Holder or any such Holder
Indemnified Party may become subject under the Securities Act or otherwise,
insofar as such claims, actions, demands, losses, damages, liabilities,
costs or reasonably incurred expenses arise out of or are based upon (i) any
untrue statement or alleged untrue statement of any material fact contained
in such registration statement, any prospectus contained therein or any
amendment or supplement thereto, or arise out of or are based upon the
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading,
or (ii) any materially inaccurate representation or breach of any material
warranty, agreement or covenant of the Company contained herein;
provided, however, that the Company will not be liable in any such
case to the extent that any such claim, action, demand, loss, damage,
liability, cost or expense is caused by an untrue statement or alleged
untrue statement or omission or alleged omission (1) made in conformity with
information furnished by such Holder in writing specifically for use in the
preparation thereof, or (2) which was cured in an amendment or supplement to
the prospectus (or any amendment or supplement thereto) delivered to the
Holder on a timely basis to permit proper delivery thereof prior to the date
on which any Option Shares were transferred or sold.




	 	(b)	 	Indemnification by the Holder. Each Holder of Option
Shares which are included in a registration statement pursuant to the
provisions of Section 5 hereof will indemnify and hold harmless the Company,
and any Person who controls the Company within the meaning of either Section 15
of the Securities Act or Section 20 of the Exchange Act, and any officer,
director, employee, agent, partner, member or affiliate of the Company (each,
an “Company Indemnified Party”) from and against, and will reimburse the
Company Indemnified Parties with respect to, any and all losses, damages,
liabilities, costs or reasonably incurred expenses to which such Company
Indemnified Parties may become subject under the Securities Act or otherwise,
insofar as such losses, damages, liabilities, costs or reasonably incurred
expenses are caused by any untrue or alleged untrue statement of any material
fact contained in such registration statement, any prospectus contained therein
or any amendment or supplement thereto, or are caused by the omission or the
alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances in
which they were made, not misleading, in each case to the extent, but only to
the extent, that such untrue statement or alleged untrue statement or omission
or alleged omission was so made solely in reliance upon and in conformity with
written information furnished by such Holder specifically for use in the
preparation thereof; provided, however, that the liability of any
Holder pursuant to this Section 9(b) shall be limited to an amount not to
exceed the net proceeds received by such Holder from the sale of Option Shares




-10-









 












pursuant to the registration statement which gives rise to such obligation
to indemnify.




	 	(c)	 	Procedures. Promptly after receipt by a party
indemnified pursuant to the provisions of Section 9(a) or Section 9(b) of
notice of the commencement of any action involving the subject matter of the
foregoing indemnity provisions, such indemnified party will, if a claim thereof
is to be made against the indemnifying party pursuant to the provisions of
Section 9(a) or Section 9(b), notify the indemnifying party of the commencement
thereof; but the omission to so notify the indemnifying party will not relieve
it from any liability which it may have to an indemnified party otherwise than
under this Section 9 and shall not relieve the indemnifying party from
liability under this Section 9, except to the extent that such indemnifying
party is materially prejudiced by such omission. In case such action is
brought against any indemnified party and such indemnified party notifies the
indemnifying party of the commencement thereof, the indemnifying party shall
have the right to participate in, and, to the extent that it may wish, jointly
with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel reasonably satisfactory to such indemnified party, and
after notice from the indemnifying party to such indemnified party of its
election to assume the defense thereof, the indemnifying party will not be
liable to such indemnified party pursuant to the provisions of Section 9(a) or
Section 9(b) for any legal or other expense subsequently incurred by such
indemnified party in connection with the defense thereof. No indemnifying
party shall be liable to an indemnified party for any settlement of any action
or claim without the consent of the indemnifying party. No indemnifying party
will consent to entry of any judgment or enter into any settlement which does
not include as an unconditional term thereof the giving by the claimant or
plaintiff to such indemnified party of a release from all liability in respect
to such claim or litigation.






	 	10.	 	SURVIVAL. The obligations of the Holder as set forth in Section 4
hereof shall survive the exercise of the Option in full and the termination of this
Option Agreement.
	 
	 	11.	 	NOTICES. Any notice required or permitted to be given hereunder shall
be in writing, and shall be either (i) personally delivered, (ii) sent by U.S.
certified or registered mail, return receipt requested, postage prepaid, or (iii) sent
by Federal Express or other reputable common carrier guaranteeing next business day
delivery, to the respective addresses of the parties set forth below, or to such other
place as any party hereto may by notice given as provided herein designate for receipt
of notices hereunder. Any such notice shall be deemed given and effective upon receipt
or refusal of receipt thereof by the primary party to whom it is to be sent.




-11-









 












To the Holder, at the address provided in the Subscription
Agreement.




	 	 	 	 	 
	 
	 	To the Company:	 	ReGen Biologics, Inc.
	 
	 	 	 	509 Commerce Street
	 
	 	 	 	Franklin Lakes, NJ 07417
	 
	 	 	 	Attention: Brion D. Umidi
	 
	 	 	 	Telecopy: 201.651.5141
	 
	 	 	 	 
	 
	 	with a copy to:	 	 
	 
	 	 	 	 
	 
	 	 	 	Pillsbury Winthrop Shaw Pittman LLP
	 
	 	 	 	1650 Tysons Boulevard
	 
	 	 	 	McLean, VA 22102
	 
	 	 	 	Attention: David C. Main, Esq.
	 
	 	 	 	Telecopy: 703.770.7901






	 	12.	 	GOVERNING LAW. This Option Agreement shall be governed by the laws of
the State of New York without reference to its principles of conflicts of laws.
	 
	 	13.	 	LITIGATION. It is the intent of the parties upon execution hereof that
this Option Agreement be deemed to have been prepared by all of the parties to the end
that no party shall be entitled to the benefit of any favorable interpretation or
construction of any term or provision hereof under any rule or law.
	 
	 	14.	 	ENTIRE AGREEMENT. This Option Agreement, together with the
Subscription Agreement and the Certificate of Designations, Preferences and Rights
relating to the Preferred Stock, contains the entire understanding between the parties
concerning the subject matter of this Option Agreement. There are no representations,
agreements, arrangements or undertakings, oral or written, between the parties relating
to the subject matter of this Option Agreement which are not fully expressed herein, in
the Subscription Agreement or in the Certificate of Designations, Preferences and
Rights relating to the Preferred Stock, and all prior agreements, to the extent they
pertain to the subject matter herein, are canceled and of no further force or effect.
This Option Agreement may not be amended or modified except in a writing signed by the
parties hereto.
	 
	 	15.	 	BINDING EFFECT. This Option Agreement shall be binding upon and inure
to the benefit of the Company and the Holder. Nothing in this Option Agreement is
intended or shall be construed to confer upon any other person any right, remedy or
claim, in equity or at law, or to impose upon any other person any duty, liability or
obligation.




-12-









 











     IN WITNESS WHEREOF, the parties have caused this Option Agreement to be duly executed as of
the date first above written.



	 	 	 	 	 
	 	REGEN BIOLOGICS, INC.

 	 
	 	/s/
BRION D. UMIDI	 
	 
	 	By: 	Brion D. Umidi 	 
	 	Its:	 Senior
VP and CFO	 
	 
	 	NAME OF HOLDER:

 	 
	 	Ivy
Healthcare Capital II, L.P.	 
	 	 	 	 
	 	 	 	 
	 	SIGNATURE:

 	 
	 	Ivy
Capital Partners II, LLC, as General Partner	 
	 	 	 	 
	 	By: 	/s/
ROBERT W. PANGIA	 
	 	 	Name: 	Robert W. Pangia
	 	 	Title:	Co-Manager
	 




-13-









 





EXHIBIT A




OPTION EXERCISE FORM




______________, 200_




ReGen Biologics, Inc.

509 Commerce Street

Franklin Lakes, NJ 07417

Attention: Brion D. Umidi

Telecopy: 201.651.5141




          The undersigned hereby irrevocably elects to exercise its rights under the Option Agreement
dated                                               , 2007 made by and between ReGen Biologics, Inc. and the undersigned, by
purchasing the number of Option Shares listed below and hereby makes payment of the Exercise Amount
listed below.




	 	 	 
	Number of Option Shares Purchased

	 	                    






	 	 	 
	Exercise Price Per Share:

	 	$                    
	 
	 	 
	Exercise Amount:

	 	$                    






     The undersigned hereby represents and warrants to the Company that all of the representations
and warranties made by the Holder in Section 7(b) of the Option Agreement are true and correct as
of the date set forth above.



     Please register and deliver the Option Shares in the name and to the address set forth below.




	 	 	 	 	 	 	 	 	 
	 
	 	Name:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 
	 	 	(Please typewrite or print in block letters)
	 
	 	 	 	 	 	 	 	 
	     
	 	Address:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	NAME OF HOLDER:
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 





	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	SIGNATURE OF HOLDER:
	 
	 	 	 	 	 	 	 	 
	     
	 	By:	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	Name:	 	 	 	 
	 
	 	 	 	 	 	 	 
	 
	 	 	 	Title: